Health Winners and Losers: Celgene

Celgene and Cephalon were down 2.4% and 3.4%, respectively, on Monday.
Publish date:

Health stocks were mixed Monday as traders received a few earnings reports but didn't see a repeat of last week's

merger frenzy


The Nasdaq Biotechnology index was down 0.3%, while its Amex counterpart was adding 0.5%.

As for the big biotech stocks,


(CELG) - Get Report




were down 2.4% and 3.4%, respectively.


(GILD) - Get Report

, which last week bid for

CV Therapeutics


, was losing 3.9%. Having been outdone by Gilead,


withdrew its offer

for CV Therapeutics on Monday.

Of the higher-volume movers on the Amex Biotech index,

Amylin Pharmaceuticals


was up 50 cents, or 4.5%, to $11.70.

Among the earnings releases,

Cypress Bioscience


swung to a second-quarter loss of $7.2 million, or 19 cents a share, as revenue fell and costs increased. Shares were down 5.8%, or 47 cents, but volume was light.




lost 7.3% after announcing that its fourth-quarter loss widened to roughly $10 million, or 11 cents a share, primarily due to a writedown and a charge.


NPS Pharmaceuticals


rose 14.2% to $5.06 a share. The company reported on Friday that it had a fourth-quarter loss. However, a Jefferies & Co. analyst raised his rating for the stock to buy from hold after an update on two late-stage drug programs and further partnership developments.

Checking in on traditional drugmakers, the Amex Pharmaceutical index added 1.4%.


(AZN) - Get Report

added 4.5%, and

Eli Lilly

(LLY) - Get Report

ticked up 3.4%.


(SNY) - Get Report

moved up 2.9%.

On the losing end,



, which


(MRK) - Get Report

plans to buy, gave up 2.8%. Merck lost 1.8%.